We are Sorry, This Page doesn't Exist

Shares of bluebird bio Inc (NASDAQ: BLUE) were sinking Tuesday morning following an adverse clinical pipeline development. read more.....»»

The new cell therapy manufacturing facility, which will open early next year, will be able to deliver highly specialized cell therapies to patients in clinical trials at UCSF's women's, children's and cancer hospitals complex across Mariposa Street......»»

Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA read more.....»»

– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and hyperinflammation shows evidence of tre.....»»

EMERYVILLE, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, .....»»

-Achieved multiple clinical and pre-clinical milestones across BridgeBio's pipeline -Delivered pipeline expansion with addition of five new drug development and discovery programs; B.....»»

- Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end 2019 cash reserv.....»»

As cancer care evolves with each new drug, treatment or therapy that emerges through important research, so too evolve the methods by which these discoveries are made......»»

AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company. What Happened The U.K.-based pharma giant said its Phase 3 POSEIDON trial produced positive results.  read more.....»»

NESS-ZIONA, Israel, Oct. 7, 2019 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB:TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for.....»»

Riding on the momentum of its recent initial public offering, a Triangle gene therapy company is launching its second potential cancer treatment into clinical trials......»»

EMERYVILLE, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent bu.....»»

Japanese drug maker Eisai Co., Ltd (OTC: ESALY) has some positive news concerning one of its pipeline candidates. read more.....»»

The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba......»»

Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy Program at the Society for .....»»

Incyte Corp.’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Inc.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Mersana Therapeutics Inc. said Monday the U.S. Food an.....»»

Mersana Therapeutics Inc. said Monday t.....»»

The FDA lifts partial clinical hold on Epizyme's lead pipeline candidate, tazemetostat's study. Epizyme, Inc. (EPZM announced that the FDA has lifted the partial clinical hold on its lead cancer candidate tazeme.....»»